| Literature DB >> 23469267 |
Aliasghar Ahmad Kiadaliri1, Johan Jarl, Georgios Gavriilidis, Ulf-G Gerdtham.
Abstract
OBJECTIVE: To evaluate the effect of alcohol cessation on the risk of developing laryngeal and pharyngeal cancers, combining available evidence in the scientific literature in a meta-analysis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23469267 PMCID: PMC3585880 DOI: 10.1371/journal.pone.0058158
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of literature search.
Characteristics of studies of the risk of laryngeal and pharyngeal cancers following drinking cessation.
| Study | Country and study years | Type of study | Study area | Mortality/morbidity | Age | Gender specific calculations | Gender cases (% male) |
| Altieri et al., 2002 | Italy and Switzerland, 1992–2000 | Case-control | Larynx | Morbidity | 30–79 | No | 91 |
| Balaram et al., 2002 | India, 1996–1999 | Case-control | Oral cavity | Morbidity | 20–85 | Yes (men only) | 100 |
| Castellsague et al., 2004 | Spain, 1996–1999 | Case-control | Oral cancer | Morbidity | < = 51–> = 70 | No | 81 |
| De Stefani et al., 2004 | Uruguay, 1997–2003 | Case-control | Hypopharyngeal, larynx | Morbidity | 30–89 | Yes (men only) | 100 |
| Franceschi et al., 2000 | Italy and Switzerland, 1992–1997 | Case-control | Oral cavity, pharynx | Morbidity | <40–79 | No | 85 |
| Garrote et al., 2001 | Cuba, 1996–1999 | Case-control | Oral cavity, oro-pharynx | Morbidity | 25–91 | No | 72 |
| Hayes et al., 1999 | Puerto Rico, 1992–1995 | Case-control | Oral cavity, pharynx, salivary gland | Morbidity | 21–79 | Yes | 81 |
| Marron et al., 2009 | – | Pooledcase-control | Oropharynx, hypopharynx, larynx,oral cavity | Morbidity | 15–80 | No | NA |
| Martinez, 1969 | Puerto Rico, 1966 | Case-control | Pharynx, oral cavity | Morbidity | NA | No | 87 |
| Rehm et al. | – | Meta-analysis | Head and neck cancer | See included | See included | See included studies | See included |
| Szymanska et al., 2011 | Brazil, Argentina and Cuba, 1998 | Case-control | Oral cavity, oro-pharynx,hypopharynx, larynx | Morbidity | <40–>80 | No | 85 |
| Takezaki et al., 1996 | Japan (Aichi), 1988–1993 | Case-control | Tongue, mouth, oropharynx, hypopharynx | Morbidity | 20–79 | No | 71 |
| Takezaki et al., 2000 | Japan (Nagoya), 1988–1997 | Case-control | Hypopharynx | Morbidity | 40–79 | Yes (men only) | 100 |
These studies were not included in the meta-analysis part of the current study.
Figure 2Risk of developing laryngeal cancer and pharyngeal cancer following drinking cessation.
Meta-analysis of changes in the odds ratios of laryngeal and pharyngeal cancers after drinking cessation compared to current drinkers.
| Variables | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 |
|
| ||||||
| Additional year of drinking cessation (dose) | 0.98 | 0.98 | ||||
| Dose*study conducted in Europe | 1.02 | |||||
| Q statistics | 18.42 | 17.58 | ||||
|
| ||||||
| Additional year of drinking cessation (dose) | 0.98 | 0.98 | 0.98 | 0.98 | 0.98 | 0.98 |
| Dose*study conducted in Europe | 0.97 | 0.97 | ||||
| Dose*study did not control for smoking | 0.95** | 0.95 | 0.95** | |||
| Dose*no matching in the study | 1.08 | 1.08 | 1.08 | |||
| Q statistic | 52.91 | 50.79 | 47.26 | 43.97** | 38.70** | 36.59** |
,**,*show 1%, 5%, and 10% significant levels, respectively.
H0: No heterogeneity.
Figure 3Risk of developing laryngeal and pharyngeal cancer for never drinkers vs. current drinkers.
Figure 4Risk decline of laryngeal and pharyngeal cancer over forty years after drinking cessation.
It should be noted that the risk is not expected to fall below that of never drinkers, even though the figures imply this.
Sensitivity analysis of the meta-analysis of changes in the odds ratio of pharyngeal cancer after drinking cessation compared to current drinkers.
| Variables | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 |
| Additional year of drinking cessation (dose) | 0.98*** | 0.98*** | 0.98*** | 0.98*** | 0.98*** | 0.98*** |
| Dose*study conducted in Europe | 0.97 | 0. | 0.97 | |||
| Dose*study did not control for smoking | 0.95** | 0.95** | 0.95** | |||
| Dose*no matching in the study | 1.08*** | 1.08*** | 1.08*** | |||
| Q statistic† | 49.48*** | 47.25*** | 43.65*** | 40.73*** | 35.28** | 33.06** |
See footnote in Table 2. Excluding studies 38 & 41.